Please join CTAC Policy Researcher Adam Cook for an informative webinar detailing an exciting new HCV treatment, Ombitasvir/Paritaprevir/ritonavir. Currently undergoing review by the Common Drug Review, this treatment is intended to treat chronic HCV, genotype 4.